Abeona Therapeutics Inc. filed a Form 8-K with the SEC on November 9, 2026, disclosing a press release covering its financial results for the quarter ended September 30, 2026, and an investor presentation disseminated the same day.

Key Highlights

  • Quarterly results disclosed: Abeona Therapeutics reported financial results for the quarter ended September 30, 2026, via a press release issued November 9, 2026.
  • Investor presentation filed: The company disseminated an investor presentation on November 9, 2026, furnished as Exhibit 99.2.
  • Exchange listing: Common Stock ($0.01 par value) trades on NASDAQ:ABEO under the Nasdaq Capital Market.
  • Signing officer: The filing was signed by Joseph Vazzano, Chief Financial Officer.
  • Not "filed" for liability purposes: The filing states that Item 2.02 and Exhibit 99.1 "shall not be deemed filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Abeona Therapeutics Furnishes Q3 2026 Financial Results and Presentation Materials

According to the filing, Abeona Therapeutics Inc., a Delaware-incorporated company headquartered at 6555 Carnegie Ave, 4th Floor, Cleveland, OH 44103, issued a press release on November 9, 2026, covering its financial results for the third quarter ended September 30, 2026. That press release was furnished as Exhibit 99.1 and incorporated by reference into Item 2.02 of the current report. The filing does not reproduce specific financial figures from the press release within the body of the 8-K itself.

Under Item 7.01, the filing discloses that Abeona also disseminated an investor presentation on November 9, 2026, furnished as Exhibit 99.2. The company, which develops gene therapies and operates in the biopharmaceutical sector, stated it "expressly disclaims any obligation to update or revise any of the information contained in the investor presentation." The filing further notes that the investor presentation is subject to discontinuation of availability at any time, at the company's discretion.

The 8-K was signed by Joseph Vazzano in his capacity as Chief Financial Officer. The filing confirms that Abeona is not classified as an emerging growth company under the applicable SEC definitions. The exhibits attached include the November 9, 2026 press release, the investor presentation of the same date, and a Cover Page Interactive Data File embedded within the Inline XBRL document.

What Was Disclosed

Abeona Therapeutics filed an 8-K on November 9, 2026, furnishing its Q3 2026 earnings press release and an investor presentation as exhibits. Neither document's specific financial figures were reproduced in the 8-K body text itself.